Sangamo Therapeutics advanced the rolling submission of a Biologics License Application (BLA) for its Fabry disease gene therapy, isaralgagene civaparvovec (ST‑920), by filing the pre‑clinical and clinical modules with the U.S. Food and Drug Administration (FDA) on March 09 2026. The company began the rolling process in December 2025 and is now moving the application forward on an ongoing basis, allowing the FDA to review completed sections as they are submitted rather than waiting for a full application.
The FDA has agreed to use the mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks as an endpoint for accelerated approval of ST‑920. This decision removes a key regulatory hurdle and could shorten the time to market for a one‑time gene therapy that addresses a serious, unmet need in Fabry disease, an X‑linked lysosomal storage disorder that currently has limited treatment options.
In addition to the BLA, Sangamo submitted an antibody‑assay companion diagnostic that has been accepted by the FDA’s Center for Devices and Radiological Health (CDRH) for Premarket Approval (PMA). The diagnostic will enable precise patient selection and ensure that only those with the appropriate biomarker profile receive the therapy, a critical component of the overall treatment strategy.
Sangamo’s financial profile remains constrained. The company has a low Piotroski F‑Score, a current ratio below 1, and a high debt‑to‑equity ratio, and it recently received a Nasdaq extension to remain listed until April 27 2026. Despite these challenges, the regulatory milestone is expected to strengthen investor confidence ahead of the company’s Q4 2025 earnings release on March 16 2026.
The global Fabry disease treatment market was valued at approximately $2.54 billion in 2023 and is projected to reach $4.93 billion by 2030. ST‑920 competes with established enzyme replacement therapies and emerging gene‑therapy candidates from companies such as Amicus Therapeutics, Sanofi, Takeda, and Chiesi‑Protalix. By securing accelerated‑approval eligibility and a companion diagnostic, Sangamo positions ST‑920 to capture a significant share of this growing market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.